User menu

Everolimus halts hepatic cystogenesis in a rodent model of polycystic-liver-disease

Bibliographic reference Temmerman, Frederik ; Chen, Feng ; Libbrecht, Louis ; Vander Elst, Ingrid ; Windmolders, Petra ; et. al. Everolimus halts hepatic cystogenesis in a rodent model of polycystic-liver-disease. In: World Journal of Gastroenterology, Vol. 23, no.30, p. 5499 (2017)
Permanent URL http://hdl.handle.net/2078.1/187625
  1. Desmet Valeer J., Pathogenesis of Ductal Plate Abnormalities, 10.1016/s0025-6196(11)63624-0
  2. Temmerman F., Missiaen L., Bammens B., Laleman W., Cassiman D., Verslype C., van Pelt J., Nevens F., Systematic review: the pathophysiology and management of polycystic liver disease : Systematic review: pathophysiology and management of polycystic liver disease, 10.1111/j.1365-2036.2011.04783.x
  3. Van Keimpema Loes, De Koning Daan B., Van Hoek Bart, Van Den Berg Aad P., Van Oijen Martijn G. H., De Man Robert A., Nevens Frederik, Drenth Joost P. H., Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases : Clinical characterization of PCLD, 10.1111/j.1478-3231.2010.02247.x
  4. KATSUYAMA Makoto, MASUYAMA Takeshi, KOMURA Ichiro, HIBINO Tsutomu, TAKAHASHI Hisahide, Characterization of a Novel Polycystic Kidney Rat Model with Accompanying Polycystic Liver., 10.1538/expanim.49.51
  5. Lager Donna J., Qian Qi, Bengal Rosemary J., Ishibashi Masahiko, Torres Vicente E., The pck rat: A new model that resembles human autosomal dominant polycystic kidney and liver disease, 10.1046/j.1523-1755.2001.00473.x
  6. Ward Christopher J., Hogan Marie C., Rossetti Sandro, Walker Denise, Sneddon Tam, Wang Xiaofang, Kubly Vicky, Cunningham Julie M., Bacallao Robert, Ishibashi Masahiko, Milliner Dawn S., Torres Vicente E., Harris Peter C., The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein, 10.1038/ng833
  7. Banales Jesús M., Masyuk Tatyana V., Gradilone Sergio A., Masyuk Anatoliy I., Medina Juan F., LaRusso Nicholas F., The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD), 10.1002/hep.22636
  8. Masyuk Tatyana V., Masyuk Anatoliy I., Torres Vicente E., Harris Peter C., Larusso Nicholas F., Octreotide Inhibits Hepatic Cystogenesis in a Rodent Model of Polycystic Liver Disease by Reducing Cholangiocyte Adenosine 3′,5′-Cyclic Monophosphate, 10.1053/j.gastro.2006.12.039
  9. Hogan M. C., Masyuk T. V., Page L. J., Kubly V. J., Bergstralh E. J., Li X., Kim B., King B. F., Glockner J., Holmes D. R., Rossetti S., Harris P. C., LaRusso N. F., Torres V. E., Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease, 10.1681/asn.2009121291
  10. van Keimpema Loes, Nevens Frederik, Vanslembrouck Ragna, van Oijen Martijn G.H., Hoffmann Aswin L., Dekker Helena M., de Man Robert A., Drenth Joost P.H., Lanreotide Reduces the Volume of Polycystic Liver: A Randomized, Double-Blind, Placebo-Controlled Trial, 10.1053/j.gastro.2009.07.052
  11. Gevers Tom J.G., Inthout Joanna, Caroli Anna, Ruggenenti Piero, Hogan Marie C., Torres Vicente E., Nevens Frederik, Drenth Joost P.H., Young Women With Polycystic Liver Disease Respond Best to Somatostatin Analogues: A Pooled Analysis of Individual Patient Data, 10.1053/j.gastro.2013.04.055
  12. Temmerman F., Gevers T., Ho T. A., Vanslembrouck R., Coudyzer W., van Pelt J., Bammens B., Pirson Y., Drenth J. P., Nevens F., Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data, 10.1111/apt.12384
  13. Temmerman Frederik, Ho Thien Ahn, Vanslembrouck Ragna, Coudyzer Walter, Billen Jaak, Dobbels Fabienne, van Pelt Jos, Bammens Bert, Pirson Yves, Nevens Frederik, Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease, 10.1016/j.cgh.2015.05.039
  14. Laplante Mathieu, Sabatini David M., mTOR Signaling in Growth Control and Disease, 10.1016/j.cell.2012.03.017
  15. Ren Xiang Shan, Sato Yasunori, Harada Kenichi, Sasaki Motoko, Furubo Shinichi, Song Jing Yu, Nakanuma Yasuni, Activation of the PI3K/mTOR Pathway Is Involved in Cystic Proliferation of Cholangiocytes of the PCK Rat, 10.1371/journal.pone.0087660
  16. Wahl Patricia R., Serra Andreas L., Le Hir Michel, Molle Klaus D., Hall Michael N., Wüthrich Rudolf P., Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD), 10.1093/ndt/gfi181
  17. Zafar Iram, Ravichandran Kameswaran, Belibi Franck A., Doctor R. Brian, Edelstein Charles L., Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease, 10.1038/ki.2010.250
  18. Qian Q., Du H., King B. F., Kumar S., Dean P. G., Cosio F. G., Torres V. E., Sirolimus Reduces Polycystic Liver Volume in ADPKD Patients, 10.1681/asn.2007050626
  19. Walz Gerd, Budde Klemens, Mannaa Marwan, Nürnberger Jens, Wanner Christoph, Sommerer Claudia, Kunzendorf Ulrich, Banas Bernhard, Hörl Walter H., Obermüller Nicholas, Arns Wolfgang, Pavenstädt Hermann, Gaedeke Jens, Büchert Martin, May Christoph, Gschaidmeier Harald, Kramer Stefan, Eckardt Kai-Uwe, Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease, 10.1056/nejmoa1003491
  20. Chrispijn Melissa, Gevers Tom J.G., Hol Jeroen C., Monshouwer Rene, Dekker Heleen M., Drenth Joost P.H., Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: Results from a randomized controlled trial, 10.1016/j.jhep.2013.03.004
  21. Mason Stephen B., Liang Yun, Sinders Rachel M., Miller Caroline A., Eggleston-Gulyas Tracy, Crisler-Roberts Robin, Harris Peter C., Gattone Vincent H., Disease Stage Characterization of Hepatorenal Fibrocystic Pathology in the PCK Rat Model of ARPKD, 10.1002/ar.21166
  22. Kapoor Sarika, Rodriguez Daniel, Mitchell Katharyn, Wüthrich Rudolf P., High Resolution Ultrasonography for Assessment of Renal Cysts in the PCK Rat Model of Autosomal Recessive Polycystic Kidney Disease, 10.1159/000443420
  23. Gao Ying, Erokwu Bernadette O., DeSantis David A., Croniger Colleen M., Schur Rebecca M., Lu Lan, Mariappuram Jose, Dell Katherine M., Flask Chris A., Initial evaluation of hepaticT1relaxation time as an imaging marker of liver disease associated with autosomal recessive polycystic kidney disease (ARPKD) : T1relaxation time as an imaging biomarker of ARPKD liver disease, 10.1002/nbm.3442
  24. Khan S, Dennison A, Garcea G, Medical therapy for polycystic liver disease, 10.1308/rcsann.2016.0023
  25. Patsenker Eleonora, Schneider Vreni, Ledermann Monika, Saegesser Hans, Dorn Christoph, Hellerbrand Claus, Stickel Felix, Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis, 10.1016/j.jhep.2010.10.044
  26. Renken C., Fischer D.-C., Kundt G., Gretz N., Haffner D., Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats, 10.1093/ndt/gfq384